(12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
ANNNNNNNNNNNNNNNNNNNN 100A 006 Left Eye Input Right Eye Input
US 20190175049A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0175049 A1 Welling ( 43 ) Pub . Date : Jun . 13 , 2019 ( 54 ) TECHNIQUES FOR ANALYZING (52 ) U . S . CI. NON -VERBAL MARKERS OF CONDITIONS CPC . .. A61B 5 /04842 (2013 . 01 ) ; A61B 5 / 7289 USING ELECTROPHYSIOLOGICAL DATA (2013 . 01) ; A61B 5 /0478 ( 2013 .01 ) ; A61B 5 /7225 ( 2013. 01 ) ; G06N 20 / 10 (2019 .01 ) (71 ) Applicant: Massachusetts Institute of Technology , Cambridge , MA (US ) ( 57 ) ABSTRACT (72 ) Inventor : Caroline Welling, Hanover, NH (US ) Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry . Sensed ( 21 ) Appl. No. : 16 / 206, 639 electrical activity of a subject' s brain is received over a time period while the subject is exposed to a visual stimulus. The ( 22 ) Filed : Nov. 30 , 2018 sensed electrical activity comprises a first frequency band Related U . S . Application Data associated with a first frequency of a first image presented to the subject ' s left eye , a second frequency band associated (60 ) Provisional application No .62 / 593 , 535, filed on Dec . with a second frequency of a second image presented to the 1 , 2017 subject ' s right eye . A set of events in the time period is determined based on the frequency bands, wherein an event Publication Classification is associated with a change from a previous perceptual event (51 ) Int. Ci. to a new perceptual event. A metric for the subject is A61B 5 /0484 ( 2006 .01 ) determined based on the set of events . The metric is ana A61B 5 /00 ( 2006 .01 ) lyzed to determine whether the subject exhibits signs asso GO6N 20 / 10 (2006 .01 ) ciated with a condition that is associated with binocular A61B 5 /0478 ( 2006 .01 ) rivalry . -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
This Table Summarizes Changes to the HF Qxq As of 10/11/2019 Question
Updated HFS Instructions (QxQs) This table summarizes changes to the HF QxQ as of 10/11/2019 Question in HF QxQ Description of Changes in HF QXQ General Instructions, pg. 3 Clarification added to rules for history Q29.d.10., pg. 40 Clarification made on how to record pulmonary hypertention Q29.d.14., pg. 41 Clarification made on how to record diastolic dysfunction Q42., pg. 42 Clarification made on how to record troponin I Section VII: Medication, pg. 54 Clarificaiton made on how to record medications Appendix A, pg. 61 Updated list of medications Edoxaban (ACOAG, Generic) Lixiana (ACOAG, Trade) Prexxartan (ARB, Trade) INSTRUCTIONS FOR COMPLETING HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM HFS Version C, 10/1/2015 HFA Version D, 10/1/2015 HF QxQ, 10/11/2019 Table of Contents Page General Instructions……………………………………………………………….. 2 Specific Items………………………………………………………………………. 3 Section l: Screening for Decompensation………………………………….. 5 Section ll: History of Heart Failure…………………………………………... 10 Section lll: Medical History ………………………………………………….. 13 Section lV: Physical Exam - Vital Signs…………………………………….. 24 Section V: Physical Exam - Findings……………………………………….. 26 Section Vl: Diagnostic Tests…………………………………………………. 31 Section Vll: Biochemical Analyses………………………………………….. 48 Section Vlll: Interventions…………………………………………………….. 51 Section lX: Medications………………………………………………………. 54 Section X: Complications Following Events………………………………… 59 Section Xl: Administrative……………………………………………………. 60 Appendix A: ARIC Heart Failure/Cardiac Drugs: ………………………………. 61 Alphabetical Sort Appendix B: Potential Scenarios of the Onset of Heart………………………. 73 Failure Event or Decompensation HF QxQ 10/11/2019 Page 1 of 73 General Instructions The HFAA form was initially used for all discharges selected for HF surveillance. It was replaced by the HFAB and HFSA forms and then updated June 2012 with HFAC and HFSB. -
Drug Antioxidant Effects a Basis for Drug Selection?
REVIEW ARTI LE Drugs 42 (4): 569-605, 1991 00 12-6667/ 91/ 00 I0-0569/ $ 18.50/0 © Adis International Limited. All rights reserved. DRU161 Drug Antioxidant Effects A Basis for Drug Selection? Barry Halliwell Pulmonary Medicine, UC Davis Medical Center, Sacramento , California, USA Contents 570 Summary 570 I. What is a Free Radical? 570 1.1 Definition of a Free Radical 57/ 1.2 Hydroxyl Radical 572 1.3 Formation of Oxygen Radicals In Vivo 574 1.4 Reactive Oxygen Species 575 1.5 Transition Metal Ions and Free Radical Reactions 575 1.6 Antioxidant Defence In Vivo: Intracellular 576 1.7 Antioxidant Defence In Vivo: Extracellular 579 2. Free Radical Damage to Cells and the Protective Ability of Antioxidants 579 2.1 Mechanisms of Cell Damage: The Molecular Targets 58/ 2.2 How to Characterise an Antioxidant 5 2 3. The Role of Free Radicals in Human Disease 582 3.1 Causation of Disease 582 3.2 A Significant Consequence of Disease Pathology 584 3.3 A General Consequence of Tissue Injury 585 3.4 What Can We Expect from Antioxidant Therapy? 586 586 4. Antioxidants in Disease Therapy 586 4.1 Use of Naturally Occurring Antioxidants and Derived Compounds 587 4.1.1 Superoxide Dismutase 587 4.1.2 Superoxide Dismutase 'Mimics' 588 4.1.3 a-Tocopherol 589 4.1.4 Ascorbic Acid (Vitamin C) 589 4.1.5 Adenosine 589 4.1.6 Lactoferrin 590 4.1.7 Nicotinamide 59/ 4.1.8 Glutathione and its Precursors 59/ 4.1.9 Carotenoids 59/ 4.2 'Synthetic' Antioxidants 59/ 4.2.1 Mercaptopropionylglycine and Other Thiols 592 4.2.2 Ebselen: A Glutathione Peroxidase Mimic? 593 4.2.3 Allopurinol, Oxypurinol and Other Xanth ine Oxidase Inhibitors 593 4.2.4 Inhibitors of the Generation of Reactive Oxygen Species by Phagocytes 595 4.2.5 Chelating Agents: Deferoxamine 595 4.2.6 Other Iron Chelators: Hydroxypyridones 596 4.2.7 Other Iron Chelators: ICRF-187 and the 'Lazaroids' 4.2.8 Probucol and Other Chain-Breaking Antioxidants 570 Drugs 42 (4) 1991 596 5. -
Customs Tariff - Schedule
CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Review Article
Free Radical Biology & Medicine, Vol. 33, No. 6, pp. 774–797, 2002 Copyright © 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0891-5849/02/$–see front matter PII S0891-5849(02)00956-5 Review Article STRUCTURE AND FUNCTION OF XANTHINE OXIDOREDUCTASE: WHERE ARE WE NOW? ROGER HARRISON Department of Biology and Biochemistry, University of Bath, Bath, UK (Received 11 February 2002; Accepted 16 May 2002) Abstract—Xanthine oxidoreductase (XOR) is a complex molybdoflavoenzyme, present in milk and many other tissues, which has been studied for over 100 years. While it is generally recognized as a key enzyme in purine catabolism, its structural complexity and specialized tissue distribution suggest other functions that have never been fully identified. The publication, just over 20 years ago, of a hypothesis implicating XOR in ischemia-reperfusion injury focused research attention on the enzyme and its ability to generate reactive oxygen species (ROS). Since that time a great deal more information has been obtained concerning the tissue distribution, structure, and enzymology of XOR, particularly the human enzyme. XOR is subject to both pre- and post-translational control by a range of mechanisms in response to hormones, cytokines, and oxygen tension. Of special interest has been the finding that XOR can catalyze the reduction of nitrates and nitrites to nitric oxide (NO), acting as a source of both NO and peroxynitrite. The concept of a widely distributed and highly regulated enzyme capable of generating both ROS and NO is intriguing in both physiological and pathological contexts. The details of these recent findings, their pathophysiological implications, and the requirements for future research are addressed in this review. -
MIRADON FPO Brand of Anisindione Tablets
R 1 2 3 4 5 3 4 F-16099775 1898 ® MIRADON FPO brand of anisindione Tablets DESCRIPTION MIRADON Tablets contain a syn- thetic anticoagulant, anisindione, an indanedione derivative. Each tablet contains 50 mg anisin- dione. They also contain: corn starch, FD&C Red No. 3, gelatin, lactose, and hydrogenated cotton- seed oil. ACTIONS Like phenindione, to which it is re- lated chemically, anisindione exercises its thera- peutic action by reducing the prothrombin activity of the blood. INDICATIONS Anisindione is indicated for the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrilla- tion with embolization, the prophylaxis and treat- ment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. CONTRAINDICATIONS All contraindications to oral anticoagulant therapy are relative rather than absolute. Contraindications should be evaluated for each patient, giving consideration to the need for and the benefits to be achieved by anticoagu- lant therapy, the potential dangers of hemor- rhage, the expected duration of therapy, and the quality of patient monitoring and compliance. Hemorrhagic Tendencies or Blood Dyscrasias: In general, oral anticoagulants are contraindi- cated in patients who are bleeding or who have hemorrhagic blood dyscrasias or hemorrhagic tendencies (eg, hemophilia, polycythemia vera, purpura, leukemia) or a history of bleeding dia- thesis. They are contraindicated in patients with recent cerebral hemorrhage, active ulceration of the gastrointestinal tract, including ulcerative colitis, or open ulcerative, traumatic, or surgical wounds. Oral anticoagulants may be contraindi- cated in patients with recent or contemplated brain, eye, or spinal cord surgery or prostatec- tomy, and in those undergoing regional or lumbar block anesthesia or continuous tube drainage of the small intestine. -
Modafinil/Armodafinil (Provigil ® /Nuvigil
Drug and Biologic Coverage Policy Effective Date ............................................ 7/1/2020 Next Review Date… ..................................... 7/1/2021 Coverage Policy Number .................................. 1501 Modafinil / Armodafinil for Individual and Family Plans Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 Obstructive Sleep Apnea Treatment Services FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 3 General Background ............................................ 3 Coding/ Billing Information ................................... 6 References .......................................................... 6 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies -
Amphetamine/Dextroamphetamine IR Generic
GEORGIA MEDICAID FEE-FOR-SERVICE STIMULANT AND RELATED AGENTS PA SUMMARY Preferred Non-Preferred Amphetamine/dextroamphetamine IR generic Adzenys ER (amphetamine ER oral suspension) Armodafinil generic Adzenys XR (amphetamine ER dispersible tab) Atomoxetine generic Amphetamine/dextroamphetamine ER (generic Concerta (methylphenidate ER/SA) Adderall XR) Dextroamphetamine IR tablets generic Aptensio XR (methylphenidate ER) Focalin (dexmethylphenidate) Clonidine ER generic Focalin XR (dexmethylphenidate ER) Cotempla XR (methylphenidate ER disintegrating Guanfacine ER generic tablet) Methylin oral solution (methylphenidate) Daytrana (methylphenidate TD patch) Methylphenidate CD/CR/ER generic by Lannett Desoxyn (methamphetamine) [NDCs 00527-####-##] and Kremers Urban [NDCs Dexmethylphenidate IR generic 62175-####-##] (generic Metadate CD) Dexmethylphenidate ER generic Methylphenidate IR generic Dextroamphetamine ER capsules generic Modafinil generic Dextroamphetamine oral solution generic Quillichew ER (methylphenidate ER chew tabs) Dyanavel XR (amphetamine ER oral suspension) Quillivant XR (methylphenidate ER oral suspension) Evekeo (amphetamine tablets) Vyvanse (lisdexamfetamine) Methamphetamine generic Zenzedi 5 mg, 10 mg IR tablets (dextroamphetamine) Methylphenidate IR chewable tablets generic Methylphenidate ER/SA (generic Concerta) Methylphenidate ER/LA/SR (generic Ritalin LA, Ritalin SR, Metadate ER) Methylphenidate ER/SA 72 mg generic Methylphenidate oral solution generic Mydayis (amphetamine/dextroamphetamine ER) Ritalin LA 10 mg -
MEDICATION GUIDE Armodafinil Tablets, C-IV Read the Medication Guide That Comes with Armodafinil Before You Start Taking It and Each Time You Get a Refill
MEDICATION GUIDE Armodafinil Tablets, C-IV Read the Medication Guide that comes with armodafinil before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your condition or treatment. What is the most important information I should know about armodafinil? Armodafinil may cause serious side effects including a serious rash or a serious allergic reaction that may affect parts of your body such as your liver or blood cells. Any of these may need to be treated in a hospital and may be life-threatening. Stop taking armodafinil and call your doctor right away or get emergency help if you have any of these symptoms: • skin rash, hives, sores in your mouth, or your skin blisters and peels • swelling of your face, eyes, lips, tongue, or throat • trouble swallowing or breathing • fever, shortness of breath, swelling of the legs, yellowing of the skin or whites of the eyes, or dark urine. If you have a severe rash with armodafinil, stopping the medicine may not keep the rash from becoming life- threatening or causing you to be permanently disabled or disfigured. Armodafinil is not approved for use in children for any medical condition. It is not known if armodafinil is safe or if it works in children under the age of 17. What is armodafinil? Armodafinil is a prescription medicine used to improve wakefulness in adults who are very sleepy due to one of the following diagnosed sleep disorders: • narcolepsy • obstructive sleep apnea (OSA). -
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.